Moderna doses first patients across four new Phase I clinical studies
Category: #health  By Pankaj Singh  Date: 2019-08-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Moderna doses first patients across four new Phase I clinical studies

Moderna, a biotech company that focuses on discovery and development of drugs and is based in Cambridge, Massachusetts, announced recently that it has initiated four new Phase I clinical trials, two of which are related to infectious diseases and two in immuno-oncology.

Additionally, in a Phase II study regarding a vaccine for melanoma, first patient has given consent for continuing with the trial. This announcement was made along with the second quarter of 2019 earnings of the company.

Apparently, Moderna’s share rose up by 14% on Nasdaq after the news was announced. The company raised over $600 million after it made its debut in stock market in November 2018, and  the largest initial public offering that was ever made by a biotech company.

According to reports, the company had dosed its first patient in the mRNA-1172’s Phase I study, which is a vaccine made for respiratory syncytial virus (RSV) as well as in mRNA-1893 trial, another vaccine made for Zika virus. For immune-oncology, the company reportedly dozed first patients in the trial for KRAS vaccine for cancer mRNA-5671’S and also a therapy for mRNA-encoding IL12.

Moderna has been developing the KRAS cancer vaccine and the RSV vaccine in partnership with Merck & Co., whereas under the partnership with MedImmune, subsidiary of AstraZeneca, a British drug maker, the company was developing IL12, under the name MEDI1191.

Patients suffering from number of solid tumors together are being co-administered with MEDI1191 with PD-L1 checkpoint inhibitor, AstraZeneca Imfinzi. Drug makers have been taking keen interest in the in the areas of developing KRAS protein for its wide expression in multiple solid tumors, and is considered undruggable owing to its structure.

Reportedly, Amgen has been in the process of developing AMG 510, that targets KRAS G12C, a form of KRAS that has shown efficacy in various patients. Various startups have been involved in the investigation of product candidates that also target KRAS mutations.

 

Source Credit- https://medcitynews.com/2019/08/moderna-builds-up-clinical-pipeline-as-multiple-new-drugs-enter-phase-i-testing/?rf=1



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Flipkart launches Loyalty Program across 5,000 retail outlets in India
Flipkart launches Loyalty Program across 5,000 retail outlets in India
By Pankaj Singh

E-commerce giant Flipkart has recently launched SuperCoin Pay, a system of currency which its customers will have the right to use across tons of retail stores in the country. Flipkart is betting on its loyalty program...

Sirnaomics reveals dose administration of 1st patient in STP705 trial
Sirnaomics reveals dose administration of 1st patient in STP705 trial
By Pankaj Singh

Sirnaomics, Inc., a clinical-stage biopharmaceutical company, has recently announced the dose administration of the 1st patient in a Phase 2a clinical trial of STP705. STP705 is a lead drug candidate develop...

Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
By Pankaj Singh

The pharma giant Pfizer Inc. has reportedly declared that the U.S. Food and Drug Administration (US FDA) has approved the sNDA (supplemental New Drug Application) for XALKORI® (crizotinib) for the treatment of chil...